Vanguard Capital Management
CNTX icon

Vanguard Capital Management’s Context Therapeutics CNTX Stock Holding History

Vanguard Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.9M Buy
3,432,052
+99
+0% +$201 ﹤0.01% 3440
2026
Q1 		$8.99M Buy
+3,431,953
New +$8.01M ﹤0.01% 2790

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's CNTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Context Therapeutics (CNTX) stake by 0% in Q2 2026, buying an estimated $201 and bringing the position to 3,432,052 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3440.

Vanguard Capital Management first reported a position in CNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.99M in Q1 2026. 80 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Vanguard Capital Management held 3,432,052 shares of Context Therapeutics worth $1.9M as of Q2 2026.
  • Vanguard Capital Management bought 99 Context Therapeutics shares in Q2 2026, an estimated $201.
  • Context Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3440 holding.
  • Vanguard Capital Management first reported a position in Context Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Context Therapeutics position peaked at $8.99M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.